The FDA is reviewing its expedited drug review program following feedback from patient groups and companies, with many urging a pause for more public input. In parallel, the FDA has initiated a safety study of the mifepristone abortion pill, which could lead to stricter distribution controls. This highlights ongoing regulatory scrutiny in the pharmaceutical sector and the complex interplay between drug approval processes and public policy. Developers and professionals in biotech and pharma should stay abreast of these evolving regulatory landscapes.
Read the full article at STAT Pharma
Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.
4
Ali NematiWritten by Ali
